Biodiversity and Environmental Research Center-BERC, Til-Nablus, Palestine.
Biodiversity and Environmental Research Center-BERC, Til-Nablus, Palestine.
J Ethnopharmacol. 2016 Jul 1;187:104-22. doi: 10.1016/j.jep.2016.04.038. Epub 2016 Apr 25.
ETHNOPHARMACOLOGICAL RELEVANCE: The use of CAM including herbal medicine as the most preferred CAM modality, among cancer patients who are taking prescription medications has shown to be highly prevalent worldwide as well as in several Middle Eastern countries, with a high percentage of the patients do not disclose their CAM use to treating physician. AIM OF THE STUDY: The current study aimed to evaluate the patterns of CAM use among two cohorts of cancer patients in Palestine over a three-year period, and to identify socio-demographic factors that are associated with CAM use. MATERIALS AND METHODS: Across-sectional survey of patients attending outpatient cancer clinics. The method was based on a semi-structured questionnaire. In order to identify safety-related concerns associated with the products listed, a literature search was conducted using different databases (PubMed, Micromedex, AltMedDex, and the Natural Medicine Comprehensive Database). RESULTS: In 472 cancer patients including 372 of the 2011 cohort; and 100 of the 2014 cohort, the overall prevalence of CAM use was 69.5%. CAM users were more likely to be ≤65 years old, village resident, being in the midst of chemotherapy, to have high interest spiritual quest, and to have no other chronic diseases. A significant number of CAM users reported using herbal preparations (98.3%, and 89.6% in the two study cohorts, respectively). In the current study, a total of 40 plant taxa belonging to 23 botanical families were reported by ≥3 cancer patients in the two cohort groups. The top most commonly used plant in the 2011 cohort group was Arum palaestinum (43.5%), while Ephedra foeminea emerged as the top most commonly utilized plant (from 0.0% in 2011 to 55.2% in the 2014 cohort), mainly due to a recent publicizing and portraying of the plant in the local media as an effective cancer herbal remedy. Safety-related concerns were associated with 33 (82.5%) herbs, including herb-drug interactions with altered pharmacokinetics (8, 20% herbs), direct toxic effects (16, 40% herbs), and increased in vitro response of cancer cells to chemotherapy (30, 75% herbs). CONCLUSIONS: CAM use, especially herbal medicine in cancer is highly prevalent in Palestine. This study has demonstrated the role of the media on the emergence of new CAM herbal therapies among cancer patients in Palestine, and discussed its potential implications on patients and for oncologists who are treating them. Some of the most widely used herbal medicines by cancer patients in the present work are known to interact with conventional anticancer drugs. Hence, the disclosure of the use of herbal remedies by patients to health professionals with sufficient training in CAM use is important for the later in order to assess whether there are any possible herbal drug interactions and/or harmful drug reactions.
民族药理学相关性:在使用处方药物的癌症患者中,包括草药在内的补充和替代医学(CAM)的使用作为最受欢迎的 CAM 模式,在全球以及一些中东国家都非常普遍,有很高比例的患者未向治疗医生透露他们的 CAM 使用情况。
研究目的:本研究旨在评估巴勒斯坦的两批癌症患者在三年内使用 CAM 的模式,并确定与 CAM 使用相关的社会人口因素。
材料和方法:对在门诊癌症诊所就诊的患者进行横断面调查。该方法基于半结构式问卷。为了识别与列出的产品相关的安全相关问题,我们使用不同的数据库(PubMed、Micromedex、AltMedDex 和天然药物综合数据库)进行了文献检索。
结果:在 472 名癌症患者中,包括 2011 队列的 372 名和 2014 队列的 100 名,CAM 使用的总体流行率为 69.5%。CAM 用户更可能是≤65 岁、农村居民、正在接受化疗、对精神探索有浓厚兴趣且没有其他慢性疾病的人。相当数量的 CAM 用户报告使用草药制剂(分别为 98.3%和 89.6%)。在本研究中,在两个队列组中,共有 40 种植物分类群被≥3 名癌症患者报告。在 2011 队列组中,最常使用的植物是巴勒斯坦白菖蒲(43.5%),而麻黄在 2014 队列中作为最常用的植物出现(从 2011 年的 0.0%到 55.2%),主要是由于最近在当地媒体上对该植物作为有效的癌症草药疗法进行了宣传和描绘。与 33 种(82.5%)草药相关的安全相关问题,包括改变药代动力学的草药-药物相互作用(8 种,20%的草药)、直接毒性作用(16 种,40%的草药)和体外癌细胞对化疗的反应增加(30 种,75%的草药)。
结论:CAM 的使用,尤其是癌症患者中的草药在巴勒斯坦非常普遍。本研究表明,媒体在巴勒斯坦癌症患者中新 CAM 草药疗法的出现中发挥了作用,并讨论了其对患者和治疗他们的肿瘤学家的潜在影响。目前工作中癌症患者最广泛使用的一些草药已知与传统抗癌药物相互作用。因此,患者向接受过充分 CAM 使用培训的卫生专业人员透露草药疗法的使用情况非常重要,以便医生评估是否存在任何可能的草药药物相互作用和/或有害的药物反应。
Complement Ther Clin Pract. 2013-9-30
J Ethnopharmacol. 2016-2-3
BMC Complement Altern Med. 2016-7-11
Complement Ther Clin Pract. 2011-7-2
J Oncol Pharm Pract. 2021-12
Complement Ther Clin Pract. 2011-10-2
Perioper Med (Lond). 2024-11-12
Oncotarget. 2024-3-5
Oncotarget. 2024-2-8
J Cancer Res Clin Oncol. 2023-7